## SACS Polyclonal Antibody

Description

| Product type | Primary Antibody |
| :--- | :--- |
| Code | BT-AP14028 |
| Host | Rabbit |
| Isotype | IgG |
| Size | $100 \mathrm{ul}, 50 \mathrm{ul}, 20 \mathrm{ul}$ |
| Immunogen | Synthesized peptide derived from human protein . at AA range: 4291-4340 |
| Mol wt | N/A |
| Species reactivity | Human, Mouse |
| Clonality | Polyclonal |
| Recommended application | IHC-p, IF |
| Concentration | $1 \mathrm{mg} / \mathrm{ml}$ |
| Full name | Sacsin |
| Synonyms | Sacsin ;DnaJ homolog subfamily C member 29;DNAJC29 |

This product is for research use only, not for use in human, therapeutic or diagnostic procedure.

## Background

This gene encodes the sacsin protein, which includes a UbL domain at the N-terminus, a DnaJ domain, and a HEPN domain at the Cterminus. The gene is highly expressed in the central nervous system, also found in skin, skeletal muscles and at low levels in the pancreas. This gene includes a very large exon spanning more than 12.8 kb . Mutations in this gene result in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), a neurodegenerative disorder characterized by early-onset cerebellar ataxia with spasticity and peripheral neuropathy. The authors of a publication on the effects of siRNA-mediated sacsin knockdown concluded that sacsin protects against mutant ataxin-1 and suggest that "the large multi-domain sacsin protein is able to recruit Hsp70 chaperone action and has the potential to regulate the effects of other ataxia proteins" (Parfitt et al., PubMed: 19208651).

## Recommended Dilution

IHC-p: 1: 50-1:300
Not yet tested in other applications.

Images
No images.

Storage
$-20^{\circ} \mathrm{C}$ for 1 year

